 Drug Synergism
"Drug Synergism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The action of a drug in promoting or enhancing the effectiveness of another drug.
| Descriptor ID |
D004357
|
| MeSH Number(s) |
G07.690.773.968.477
|
| Concept/Terms |
Drug Synergism- Drug Synergism
- Drug Synergisms
- Synergism, Drug
- Synergisms, Drug
Drug Potentiation- Drug Potentiation
- Drug Potentiations
- Potentiation, Drug
- Potentiations, Drug
Drug Augmentation- Drug Augmentation
- Augmentation, Drug
- Augmentations, Drug
- Drug Augmentations
|
Below are MeSH descriptors whose meaning is more general than "Drug Synergism".
Below are MeSH descriptors whose meaning is more specific than "Drug Synergism".
This graph shows the total number of publications written about "Drug Synergism" by people in this website by year, and whether "Drug Synergism" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 5 | 5 | | 1996 | 0 | 6 | 6 | | 1997 | 0 | 4 | 4 | | 1998 | 0 | 7 | 7 | | 1999 | 0 | 6 | 6 | | 2000 | 0 | 3 | 3 | | 2001 | 0 | 7 | 7 | | 2002 | 0 | 8 | 8 | | 2003 | 0 | 9 | 9 | | 2004 | 0 | 8 | 8 | | 2005 | 0 | 8 | 8 | | 2006 | 1 | 7 | 8 | | 2007 | 0 | 4 | 4 | | 2008 | 0 | 13 | 13 | | 2009 | 0 | 9 | 9 | | 2010 | 0 | 8 | 8 | | 2011 | 0 | 13 | 13 | | 2012 | 0 | 7 | 7 | | 2013 | 0 | 9 | 9 | | 2014 | 2 | 8 | 10 | | 2015 | 0 | 8 | 8 | | 2016 | 1 | 7 | 8 | | 2017 | 0 | 12 | 12 | | 2018 | 0 | 7 | 7 | | 2019 | 0 | 1 | 1 | | 2020 | 0 | 5 | 5 | | 2021 | 0 | 6 | 6 | | 2024 | 2 | 3 | 5 | | 2025 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Synergism" by people in Profiles.
-
Kaplan JB, Muzaleva A, Sailer M, Huizinga RB, Kridin K. Synergistic activity of dispersin B and benzoyl peroxide against Cutibacterium acnes/Staphylococcus epidermidis dual-species biofilms. PLoS One. 2025; 20(3):e0320662.
-
Esquer H, Zhou Q, LaBarbera DV. Targeted Inhibition of CHD1L by OTI-611 Reprograms Chemotherapy and Targeted Therapy-Induced Cell Cycle Arrest and Suppresses Proliferation to Produce Synergistic Antitumor Effects in Breast and Colorectal Cancer. Cells. 2025 02 20; 14(5).
-
Shin E, Dousa KM, Taracila MA, Bethel CR, Nantongo M, Nguyen DC, Akusobi C, Kurz SG, Plummer MS, Daley CL, Holland SM, Rubin EJ, Bulitta JB, Boom WH, Kreiswirth BN, Bonomo RA. Durlobactam in combination with ?-lactams to combat Mycobacterium abscessus. Antimicrob Agents Chemother. 2025 Feb 13; 69(2):e0117424.
-
Sala R, Esquer H, Kellett T, Clune S, Awolade P, Pike LA, Zhou Q, Messersmith WA, LaBarbera DV. CHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models. Int J Mol Sci. 2024 Dec 07; 25(23).
-
Murayama M, Hosonuma M, Kuramasu A, Kobayashi S, Sasaki A, Baba Y, Narikawa Y, Toyoda H, Isobe J, Funayama E, Tajima K, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Hamada K, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Horiike A, Sambe T, Tsuji M, Wada S, Kobayashi S, Shimane T, Tsunoda T, Kobayashi H, Kiuchi Y, Yoshimura K. Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody. Sci Rep. 2024 05 17; 14(1):11325.
-
Dousa KM, Shin E, Kurz SG, Plummer M, Nantongo M, Bethel CR, Taracila MA, Nguyen DC, Kreiswith BN, Daley CL, Remy KE, Holland SM, Bonomo RA. Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus. mBio. 2024 Jun 12; 15(6):e0060924.
-
Pandey K, Acharya A, Pal D, Jain P, Singh K, Durden DL, Kutateladze TG, Deshpande AJ, Byrareddy SN. SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2. Antiviral Res. 2024 07; 227:105904.
-
Nguyen DC, Dousa KM, Kurz SG, Brown ST, Drusano G, Holland SM, Kreiswirth BN, Boom WH, Daley CL, Bonomo RA. "One-Two Punch": Synergistic ?-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes. Clin Infect Dis. 2021 10 20; 73(8):1532-1536.
-
Polutchko SK, Glime GNE, Demmig-Adams B. Synergistic Action of Membrane-Bound and Water-Soluble Antioxidants in Neuroprotection. Molecules. 2021 Sep 04; 26(17).
-
Wooten DJ, Meyer CT, Lubbock ALR, Quaranta V, Lopez CF. MuSyC is a consensus framework that unifies multi-drug synergy metrics for combinatorial drug discovery. Nat Commun. 2021 07 29; 12(1):4607.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|